BiomX Inc PHGE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PHGE is a good fit for your portfolio.
News
-
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
-
BiomX Announces the Appointment of Susan Blum to its Board of Directors
-
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
-
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
-
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
-
Thinking about buying stock in Marpai, Axcelis Technologies, Amylyx Pharmaceuticals, Biomx, or X4 Pharmaceuticals?
-
Thinking about buying stock in Mirum Pharmaceuticals, Entera Bio, Andean Precious Metals, Viatris, or Biomx?
Trading Information
- Previous Close Price
- $0.34
- Day Range
- $0.31–0.34
- 52-Week Range
- $0.19–0.86
- Bid/Ask
- $0.33 / $0.34
- Market Cap
- $18.22 Mil
- Volume/Avg
- 78,599 / 2.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- 2.26
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 71
- Website
- https://www.biomx.com
Valuation
|
Metric
|
PHGE
|
|---|---|
Price/Earnings (Normalized) | 2.26 |
Price/Book Value | 5.07 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PHGE
Financial Strength
|
Metric
|
PHGE
|
|---|---|
Quick Ratio | 1.39 |
Current Ratio | 1.58 |
Interest Coverage | −10.34 |
Quick Ratio
PHGE
Profitability
|
Metric
|
PHGE
|
|---|---|
Return on Assets (Normalized) | −68.00% |
Return on Equity (Normalized) | −197.03% |
Return on Invested Capital (Normalized) | −80.36% |
Return on Assets
PHGE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xrrdhsrqv | Qybl | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cxbkysr | Zdkwnmd | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Clfccdtnx | Kyjyn | $99.5 Bil | |
MRNA
| Moderna Inc | Znvwpsf | Ymwg | $38.8 Bil | |
ARGX
| argenx SE ADR | Tngyhtfwp | Zgrsb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fsbhhqkmt | Kjxj | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Klmmfkyx | Tppcl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hvvpbyzgg | Jbrwvm | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dgbbrzdd | Rbnzzyj | $12.5 Bil | |
INCY
| Incyte Corp | Dcnxmmv | Lbfbskf | $11.6 Bil |